Business mix
- The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH).
- It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC).
- In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer.
- Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials.
Current key questions
- Can the company's products, services, or pipeline expand adoption within biotechnology?
- How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
- Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
